Injection, ocrelizumab, 1 mg
Products billed under this code include Ocrevus.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ocrevus.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ocrevus | Genentech, Inc. | 50242-0150-01 | 300 | $18,206.70 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $60.689 | −$0.281 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $60.97 | +$1.374 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $59.596 | +$0.272 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $59.324 | −$0.09 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $59.414 | −$0.29 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $59.704 | +$1.897 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $57.807 | −$0.959 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $58.766 | −$1.032 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $59.798 | −$0.453 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $60.251 | +$1.495 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $58.756 | −$0.995 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $59.751 | −$0.794 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $60.545 | −$0.872 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $61.417 | +$2.45 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $58.967 | −$0.687 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $59.654 | −$0.428 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $60.082 | −$0.41 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $60.492 | +$1.999 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $58.493 | −$0.414 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $58.907 | +$0.616 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $58.291 | −$0.285 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $58.576 | +$1.332 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $57.244 | −$0.082 | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $57.326 | – | 1 MG | Injection, ocrelizumab, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.